Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA panel review date set for PMR (percutaneous myocardial revascularisation) therapy:

This article was originally published in Clinica

Executive Summary

A US FDA advisory panel is to review a PMA application for a minimally invasive heart laser technique for relieving angina. The percutaneous myocardial revascularisation (PMR) method, developed by Sunnyvale, California-based Eclipse Surgical Technologies, will be assessed by the agency's circulatory system devices panel on July 9. PMR has been shown in recent clinical trials to significantly reduce angina, says Eclipse, which already has US approval for a surgical version of the treatment. Minimally invasive heart laser therapy came under scrutiny last year, after Biosense Webster, another firm involved in the heart laser field, released poor results from its direct myocardial revascularisation study (see Clinica No 941, p 31).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT071210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel